Krishnan Krish S 4

What Happened

• Krishnan Krish S, a reported 10% owner of Krystal Biotech (KRYS), sold a total of 25,000 shares in a series of open-market transactions on June 4, 2026. The trades were executed at prices ranging roughly from $300.75 to $312.23, for aggregate proceeds of approximately $7,702,983. These sales were reported on a Form 4 filed June 5, 2026.
• This was a series of sales (code S) — not purchases or option exercises — and were carried out pursuant to a previously adopted Rule 10b5-1 trading plan (adopted Sept 4, 2025; effective Dec 4, 2025; terminates Dec 4, 2026, or earlier).

Key Details

• Transaction date: 2026-06-04; filing date: 2026-06-05 (timely).
• Shares sold: 25,000 total; Aggregate proceeds: ~$7.70 million.
• Price range reported: approximately $300.75 to $312.23 (many lots were executed in multiple trades; several entries reflect weighted-average prices per footnotes).
• Shares owned after transaction: Not specified in this Form 4 filing.
• Notable footnotes: sales were made under a Rule 10b5-1 plan (F2); several lots were executed as multiple trades with weighted-average prices and are detailed by footnotes (F3–F11); holdings by related trusts/spouse are excluded from this Form 4 and reported separately (F1, F12, F13).
• Transaction type code: S = Sale.

Context

• Sales made under a Rule 10b5-1 plan are typically prearranged and do not by themselves indicate a change in the insider’s view of the company; they are often used to allow routine disposition of shares while avoiding accusations of trading on material nonpublic information.
• As a 10% owner (not solely an executive trade), these filings reflect large-holder dispositions. Retail investors should view this as factual disclosure of insider selling activity but avoid inferring motivation from the sale alone.